BIIB as of Nov 1 · 20:05 ET
BIIBNasdaqBiological Products, (No Diagnostic Substances)

Biogen Inc. · Brief

Next report

95 days

Feb 5 · before openest.Q4 FY26

Expected move

No implied move.

Implied vs realized

8 reportsHistory
2 of 5≥ implied
avg implied
±4.7%
avg realized
±4.0%
Feb 12 '25—▼−4.28%—
May 1 '25—▼−0.12%—
Jul 31 '25±5.4%▲+1.07%×0.20
Oct 30 '25±4.9%▲+1.18%×0.24
Feb 6 '26±4.2%▲+8.53%×2.03
Q1 FY26±4.1%▲+6.00%×1.48
Q2 FY26—▲+1.76%—
Q3 FY26±4.7%▼−3.43%×0.74
quarterimplied−10%0+10%realized×
Q3 FY26±4.7%▼−3.43%×0.74
Q2 FY26—▲+1.76%—
Q1 FY26±4.1%▲+6.00%×1.48
Feb '26±4.2%▲+8.53%×2.03
Oct '25±4.9%▲+1.18%×0.24
Jul '25±5.4%▲+1.07%×0.20
2 older reports
May '25—▼−0.12%—
Feb '25—▼−4.28%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Feb 5 report · est.

—

Linked exposure

BIIB report session
× = co-movement · max 501dSource: SEC filings · market data

Latest changes

30 daysAll changes
Oct 14impliedImplied move: ±6.7% into Oct 28 earnings (Oct 14 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.